CYC140

· Cyclacel Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CYC140, covering 2024-02-07 to 2024-09-19. Get the full timeline:

Most recent: Clinical Trial Update: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS [Phase 1]